Lansdale, PA, United States of America

Micael Guillot

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 2016-2018

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Micael Guillot: Innovator in Pharmaceutical Formulations

Introduction: Micael Guillot, a distinguished inventor based in Lansdale, PA, has made significant contributions to the field of pharmaceuticals. With three patents to his name, he has focused on developing innovative formulations that enhance drug delivery and efficiency.

Latest Patents: One of Micael's latest patents involves a rapidly dispersible dosage form of oxcarbazepine. This innovative formulation provides a high-dose orodispersible dosage form of oxcarbazepine, incorporating drug-containing particles within a porous bound matrix. The dosage form is designed to disperse in saliva or water in less than 15 seconds, while maintaining sufficient hardness to withstand handling and storage. This advancement can be pivotal in treating various diseases or disorders that are responsive to oxcarbazepine or its derivatives.

Career Highlights: Micael has worked extensively with Aprecia Pharmaceuticals Company and Aprecia Pharmaceuticals LLC, where he has honed his expertise in pharmaceutical innovations. His work has contributed to the development of cutting-edge technologies in drug formulation and delivery.

Collaborations: Throughout his career, Micael has collaborated with notable colleagues, including Jules S. Jacob and Kelly E. Caputo. These collaborations have significantly enhanced his research and development endeavors, leading to groundbreaking innovations in pharmaceutical products.

Conclusion: Micael Guillot stands out as a noteworthy inventor in the pharmaceutical industry. His commitment to developing faster and more effective drug delivery systems is set to make a lasting impact on patient care and treatment outcomes. Through his patents and collaborations, he continues to pave the way for future innovations in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…